Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma.
The goal of this study was to evaluate the efficacy of firmonertinib neoadjuvant in patients with resectable stage II-IIIB EGFR-mutated non-small cell lung cancer (NSCLC) by major pathologic response (MPR).